VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Aged 18 years or older, male or female             │ Aged 18 years or older, male or female             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systolic heart failure with New York Heart         │ Systolic heart failure with New York Heart         │     100 │
│ Association (NYHA) class II-III                    │ Association (NYHA) class II-III                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Left ventricular ejection fraction (LVEF) less     │ Left ventricular ejection fraction (LVEF) less     │     100 │
│ than 40% by echocardiography during screening and  │ than 40% by echocardiography during screening and  │         │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ SCH (TSH: upper limits of normal (ULN) -10mIU/L,   │ SCH (TSH: upper limits of normal (ULN) -10mIU/L,   │     100 │
│ and FT4 level within reference range)              │ and FT4 level within reference range)              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Having received standard HF therapy for at least 2 │ Having received standard HF therapy for at least 2 │     100 │
│ weeks, having reached target dose or max tolerable │ weeks, having reached target dose or max tolerable │         │
│ dose                                               │ dose                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Provided informed consent                          │ Provided informed consent                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute heart failure or acute exacerbation of       │ Acute heart failure or acute exacerbation of       │     100 │
│ chronic heart failure within the past 2 weeks      │ chronic heart failure within the past 2 weeks      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Scheduled cardiac resynchronization therapy or     │ Scheduled cardiac resynchronization therapy or     │     100 │
│ heart transplantation                              │ heart transplantation                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of malignant tumor or life expectancy      │ History of malignant tumor or life expectancy      │     100 │
│ under 12 months                                    │ under 12 months                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Already on medications that may affect thyroid     │ Already on medications that may affect thyroid     │     100 │
│ function (L-T4, carbimazole, propylthiouracil,     │ function (L-T4, carbimazole, propylthiouracil,     │         │
│ amiodarone, lithium)                               │ amiodarone, lithium)                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy and lactation period                     │ Pregnancy and lactation period                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another clinical trial within the │ Participation in another clinical trial within the │     100 │
│ past 30 days                                       │ past 30 days                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindication or intolerance to evidence-based  │ Contraindication or intolerance to evidence-based  │     100 │
│ therapy for CHF, such as beta-blocker,             │ therapy for CHF, such as beta-blocker,             │         │
│ angiotensin-converting enzyme inhibitor or         │ angiotensin-converting enzyme inhibitor or         │         │
│ angiotensin receptor blocker                       │ angiotensin receptor blocker                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to the trial treatment(s)   │ Known hypersensitivity to the trial treatment(s)   │     100 │
│ or diluents (when applicable), including placebo   │ or diluents (when applicable), including placebo   │         │
│ or other comparator drug(s)                        │ or other comparator drug(s)                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Untreated adrenal insufficiency                    │ Untreated adrenal insufficiency                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Untreated pituitary insufficiency                  │ Untreated pituitary insufficiency                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Untreated thyrotoxicosis                           │ Untreated thyrotoxicosis                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with levothyroxine must not be initiated │ Treatment with levothyroxine must not be initiated │     100 │
│ in patients with acute myocardial infarction,      │ in patients with acute myocardial infarction,      │         │
│ acute myocarditis, or acute pancarditis            │ acute myocarditis, or acute pancarditis            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any disorder which, in the opinion of the          │ Any disorder which, in the opinion of the          │     100 │
│ investigator, might jeopardise subject's safety or │ investigator, might jeopardise subject's safety or │         │
│ compliance with the protocol                       │ compliance with the protocol                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe renal dysfunction (eGFR≤30 ml/min/1.73m2)   │ Severe renal dysfunction (eGFR=30 ml/min/1.73m2)   │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant hepatic impairment (Serum GPT \> 120   │ Significant hepatic impairment (Serum GPT > 120    │      99 │
│ U/L)                                               │ U/L)                                               │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                 │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ History of malignant tumor or life expectancy │      36 │
│                                   │ under 12 months                               │         │
╘═══════════════════════════════════╧═══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 96.95454545454545
OverAll Ratio: 97.97727272727272
